semaglutide prediabetes progression to diabetes step trial Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 A, Trial design. Semaglutide was

postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Hach M, Dorthe Kot Engelund, Mysling S, et al

The liver and mitochondria then lose their main defense against oxidative damage, allowing inflammation and toxin buildup to worsen

With headlines and social media amplifying new findings, counseling patients on GLP-1 therapies has become more complex

A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes

For patients with genetic predispositions, anxiety may persist longer and require behavioral intervention, medication adjustment, or consultation with a mental health provider